Skip to content
Nonprofiteer
← GLIOBLASTOMA FOUNDATION INC

Form 990 for tax year 2022

Filed by GLIOBLASTOMA FOUNDATION INC.

Totals

Total revenue
$1,471,550
Total expenses
$853,578
Contributions and grants received
$1,513,382
Grants paid
$180,000
Program service revenue
$0
Investment income
-$41,832
Other revenue
$0
Total assets, end of year
$1,781,399
Total liabilities, end of year
$0
Net assets or fund balances, end of year
$1,781,399
Program services expenses (Part IX)
$605,314
Management and general expenses
$227,245
Fundraising expenses
$21,019
Program service expenses (Part III)
$605,314

Program services were 70.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1f · All other contributions, gifts and grants

    $1,513,382

  • 3 · Investment income

    total $14,333 · excluded $14,333

  • 7a · Gross sales of assets other than inventory

    securities $439,139

  • 7b · Less cost or other basis and sales expenses

    securities $495,304

  • 7c · Gain or loss

    securities -$56,165

  • 7d · Net gain or loss

    total -$56,165 · excluded -$56,165

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $180,000 · program services $180,000

  • 5 · Compensation of officers, directors and key employees

    total $192,826 · program services $183,187 · management and general $9,639

  • 10 · Payroll taxes

    total $69,943 · program services $66,446 · management and general $3,497

  • 11b · Fees: legal

    total $132,316 · management and general $132,316

  • 12 · Advertising and promotion

    total $91,507 · program services $91,507

  • 13 · Office expenses

    total $53,161 · management and general $38,730 · fundraising $14,431

  • 14 · Information technology

    total $29,229 · program services $22,641 · fundraising $6,588

  • 17 · Travel

    total $49,240 · program services $49,240

  • 19 · Conferences, conventions and meetings

    total $11,614 · program services $11,614

  • 22 · Depreciation, depletion and amortization

    total $1,058 · management and general $1,058

  • 24a · Other expenses: CONTRACT SERVICES

    total $26,665 · management and general $26,665

  • 24b · Other expenses: BANK FEES

    total $8,661 · management and general $8,661

  • 24c · Other expenses: MISCELLANEOUS

    total $4,280 · management and general $4,280

  • 24d · Other expenses: MEALS AND ENTERTAINMENT

    total $2,399 · management and general $2,399

  • 24e · All other expenses

    total $679 · program services $679

Balance sheet

Part X, book values.

  • 2 · Savings and temporary cash investments

    beginning of year $698,213 · end of year $1,034,846

  • 3 · Pledges and grants receivable

    beginning of year $0 · end of year $18,250

  • 10a · Land, buildings and equipment: cost or other basis

    $5,290

  • 10b · Land, buildings and equipment: accumulated depreciation

    $1,394

  • 10c · Land, buildings and equipment, net

    beginning of year $4,954 · end of year $3,896

  • 12 · Investments: other securities

    beginning of year $820,769 · end of year $724,407

  • 27 · Net assets without donor restrictions

    beginning of year $1,523,936 · end of year $1,781,399

Mission and programs · 2022

Mission

AS THE FIRST AND LEADING NATIONAL NONPROFIT DEVOTED TO GLIOBLASTOMA, THE MISSION OF THE GLIOBLASTOMA FOUNDATION IS TO FUND LEADING-EDGE RESEARCH FOR A CURE FOR GLIOBLASTOMA, PROVIDE PATIENT SUPPORT RESOURCES, AND RAISE AWARENESS OF THIS RARE, GRADE 4 BRAIN CANCER.

  • THE RESEARCH ACHIEVEMENTS OF THE GLIOBLASTOMA FOUNDATION IN 2022 INVOLVED CONTINUING FUNDING FOR LEADING EDGE RESEARCH FOR TARGETED TREATMENTS FOR GLIOBLASTOMA, PROVIDING PATIENT SUPPORT RESOURCES FOR FAMILIES AND PATIENTS DIAGNOSED WITH GLIOBLASTOMA, AND RAISING AWARENESS OF THIS RARE GRADE 4 BRAIN CANCER. DURING THE 2022 YEAR WE CONTINUED TO FUND RESEARCH FOR THE COMBINATION DRUG THERAPY OF LOMUSTINE AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS, FUNDED RESEARCH INTO PATIENT AND CAREGIVER QUALIFY OF LIFE AFTER DIAGNOSIS RESEARCH, AND A TARGETED RESEARCH STUDY ON GLIOBLASTOMA CANCER CELL METABOLISM PROCESSES AND DRUGS TO STOP GLIOBLASTOMA CELL GROWTH. WE ALSO MOVED FORWARD ON OUR GOAL TO MANUFACTURE LOMUSTINE AT A REDUCED RATE FOR PATIENTS BY PARTNERING WITH CONTINUITY PHARMA IN THE PRODUCTIVE OF LOMUSTINE ACTIVE PHARMACEUTICAL INGREDIENT. THIS PROJECT IS CURRENTLY UNDERWAY TO BRING LOMUSTINE TO PATIENTS AT A LOWER COST. WE ALSO CONTINUED OUR PATIENT PROGRAMS TO PROVIDE CLINICAL TRIALS MATCHING TO PATIENTS AFTER A GLIOBLASTOMA DIAGNOSIS AND CONTINUED TO HOST OUR AWARD-WINNING SUPPORT GROUP FOR PATIENTS AND CAREGIVERS, CALLED THE GLIOBLASTOMA SUPPORT CIRCLE.

    Expenses $605,314 · Grants $180,000

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Neelam Kwatra

    PRESIDENT

    Total calculated
    $0
    Hours/week
    4

  • Madan Kwatra

    TREASURER/SECRETARY

    Total calculated
    $0
    Hours/week
    4

  • Gita Kwatra

    CEO

    Total calculated
    $221,249
    From this org
    $202,250
    From related orgs
    $0
    Other
    $18,999
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $202,250
    Bonus
    $0
    Other
    $0
    Deferred
    $11,354
    Nontaxable benefits
    $7,645
    Filer's total
    $221,249

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

Provenance

Return type
form_990
Tax year
2022
Filed
15 November 2023
IRS schema version
2022v5.0
Source object
202333199349312963

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.